Your session is about to expire
← Back to Search
CAR-T Cell Therapy for B-Cell Lymphoma
Study Summary
This trial is testing a new cancer treatment that combines T cells and antibodies to create a more effective treatment than either alone. So far it has caused side effects including cytokine release syndrome and neurotoxicity, but the goal is to find a dose of the second study drug, AP1903, that reduces the severity of the cytokine release syndrome and/or neurotoxicity, but still allows the remaining iC9-CAR19 cells to effectively fight the lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have received treatments specific to my type of lymphoma.I am able to care for myself but may not be able to do active work.I do not have an active infection with any major viruses.My tumor is blocking my airways.I am currently taking high doses of corticosteroids.My organs are functioning well enough for treatment.I haven't taken specific medications recently.My organs are functioning well enough for treatment.My diagnosis is B-cell Non-Hodgkin Lymphoma.My lymphoma has spread to my brain or spinal cord.I am 18 years old or older.
- Group 1: Single Arm iC9.CAR19 T cells
- Group 2: Expansion Cohort iC9-CAR19 cells
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you elucidate any other experiments involving iC9-CAR19 T cells?
"Currently, there are 958 clinical trials researching the efficacy of iC9-CAR19 T cells. Out of those studies, 176 have reached Phase 3 and a majority of them can be found in Philadelphia pa; however, 32557 locations total are running these trial investigations."
Is the utilization of iC9-CAR19 T cells potentially perilous for individuals?
"The limited clinical evidence for the safety and efficacy of iC9-CAR19 T cells has resulted in a score of 1 on our team's scale."
Is this research endeavor currently recruiting participants?
"According to clinicaltrials.gov, this medical experiment is currently seeking volunteers. This trial was initially announced on March 12th 2019 and the most recent edit took place on December 2nd 2021."
In what conditions is iC9-CAR19 T cell therapy employed?
"iC9-CAR19 T cells have been prescribed to patients with multiple sclerosis and other illnesses, including acute myelocytic leukemia, retinoblastoma, and multiple myeloma."
What is the current sample size of participants receiving treatment in this research?
"Affirmative. Clinicaltrials.gov's data shows that the trial, which was initially posted on March 12th 2019, is presently seeking patients. The study aims to recruit 30 individuals from a single medical centre."
Share this study with friends
Copy Link
Messenger